News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Zeltia Group (18494051.MA) Fails to Win U.K. Backing for Ovarian Cancer Drug


3/11/2011 6:33:17 AM

Bloomberg -- Zeltia SA (ZEL)’s Yondelis failed to win the recommendation of the U.K.’s health-cost agency as a treatment for ovarian cancer, even after the company offered to limit the expense of the medicine.

Read at Bloomberg
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES